Literature DB >> 14723982

Drug combinations for malaria: time to ACT?

Patrick E Duffy1, Theonest K Mutabingwa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14723982     DOI: 10.1016/S0140-6736(03)15230-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

Review 1.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

3.  Screening of traditionally used plants for in vivo antimalarial activity in mice.

Authors:  Esther Innocent; Mainen J Moshi; Pax J Masimba; Zakaria H Mbwambo; Modest C Kapingu; Appolinary Kamuhabwa
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-03-07

4.  Antiplasmodial activity of artecyclopentyl mether a new artemisinin derivative and its effect on pathogenesis in Plasmodium yoelii nigeriensis infected mice.

Authors:  Jyoti Agarwal; Suriya Pratap Singh; Debabrata Chanda; Dnyaneshwar Umrao Bawankule; Rajendra Singh Bhakuni; Anirban Pal
Journal:  Parasitol Res       Date:  2011-05-04       Impact factor: 2.289

5.  Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.

Authors:  Colm Morrissey; Byron Gallis; Jeffrey W Solazzi; Byung Ju Kim; Roman Gulati; Funda Vakar-Lopez; David R Goodlett; Robert L Vessella; Tomikazu Sasaki
Journal:  Anticancer Drugs       Date:  2010-04       Impact factor: 2.248

6.  Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.

Authors:  Jamin A Willoughby; Shyam N Sundar; Mark Cheung; Antony S Tin; Jaime Modiano; Gary L Firestone
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

7.  Implementation of artemether-lumefantrine treatment policy for malaria at health facilities in Tanzania.

Authors:  V Mugoyela; O Minzi
Journal:  Risk Manag Healthc Policy       Date:  2011-09-06

8.  Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam.

Authors:  S Patrick Kachur; Carolyn Black; Salim Abdulla; Catherine Goodman
Journal:  Malar J       Date:  2006-03-29       Impact factor: 2.979

9.  Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa.

Authors:  Karen I Barnes; David N Durrheim; Francesca Little; Amanda Jackson; Ushma Mehta; Elizabeth Allen; Sicelo S Dlamini; Joyce Tsoka; Barry Bredenkamp; D Jotham Mthembu; Nicholas J White; Brian L Sharp
Journal:  PLoS Med       Date:  2005-10-04       Impact factor: 11.069

10.  The benefits of artemisinin combination therapy for malaria extend beyond the individual patient.

Authors:  Paul Garner; Patricia M Graves
Journal:  PLoS Med       Date:  2005-04-26       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.